reports
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Thera...
GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers: No dose limiting toxicity reached to date, enabling recruitment of a third patient cohortGNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients, warrant...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combin...
GENFIT : GNS561 montre une activité antitumorale prometteuse en combinaison thérapeutique Données préliminaires très encourageantes de l’étude de Phase 1b en cours évaluant le médicament expérimental GNS561 associé à un inhibiteur de MEK (MEKi) dans le cholangiocarcinome (CCA) avec mutation KRAS, positionnant cette combinaison innovante comme une nouvelle approche thérapeutique potentielle pour les cancers difficiles à traiter : Pas de toxicité dose-limitante observée à ce jour, permettant la poursuite du recrutement d’une troisième cohorte de patientsLa combinaison GNS561 + MEKi a démontré...
GENFIT Announces Appointment of new Chief Medical Officer
GENFIT Announces Appointment of new Chief Medical Officer Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 27, 2025 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the appointment of Dr. Pejvack Motlagh, the new Chief Medical Officer of GENFIT. Member of the Executive Committee, Dr. Motlagh will oversee the strategy, direction, and execution of GENFIT’s clinical development plans and lead the Clinical (Operations and Strategy), Biometri...
GENFIT annonce la nomination d’un nouveau Directeur Médical
GENFIT annonce la nomination d’un nouveau Directeur Médical Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 27 novembre 2025 – GENFIT (Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui la nomination du Dr. Pejvack Motlagh en tant que nouveau Directeur Médical de GENFIT. Membre du Comité Exécutif, le Dr Motlagh supervisera la stratégie, l’orientation et l’exécution des plans de développement clinique de GENFIT, et dirigera les équi...
- Emira Sagaama
- Emmanuel Matot
- Emira Sagaama
- Emmanuel Matot
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
- Marc Hesselink
- CFA
- Thymen Rundberg
Fastned/Ongoing bond raises, a lot more is needed/HOLD
Fastned's 3Q25 trading update showed charging volume growth picked up slightly vs prior quarters but remains below BEV penetration growth. We modestly raise volume estimates yet expect growth to slow and stay under BEV penetration levels and stay uncomfortable on the significant funding gap. We maintain our HOLD rating and lift our target price to €20.50 per share (from €20).
Imerys S.A.: 1 director
A director at Imerys S.A. bought 630,576 shares at 22.766EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
GENFIT Reports Third Quarter 2025 Financial Information and Provides a...
GENFIT Reports Third Quarter 2025 Financial Information and Provides a Corporate Update Cash and cash equivalents totaled €119.0 million as of September 30, 2025€39.2 million in revenues for the nine months ended September 30, 2025, including the €26.5 million milestone payment following pricing and reimbursement approval of Iqirvo® (elafibranor) in three major European markets Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients wit...
GENFIT : Information financière du troisième trimestre 2025 et point s...
GENFIT : Information financière du troisième trimestre 2025 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 119,0 millions d’euros au 30 septembre 202539,2 millions d’euros de revenus pour les neuf premiers mois de 2025, incluant un paiement d’étape de 26,5 millions d’euros à la suite de l’approbation du prix et du remboursement d’Iqirvo® (élafibranor) dans trois marchés européens majeurs Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 20 novembre 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceuti...
GENFIT announces effectiveness of voluntary delisting of American Depo...
GENFIT announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); November 20, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Global Select Market (“Nasdaq”) has become effective. Each ADS represents one ordinary s...
GENFIT annonce la réalisation du retrait volontaire de ses « American ...
GENFIT annonce la réalisation du retrait volontaire de ses « American Depositary Shares » du Nasdaq Stock Market Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 20 novembre 2025 – GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies rares du foie pouvant engager le pronostic vital, annonce aujourd’hui que le retrait volontaire du Nasdaq Global Select Market (« Nasdaq ») des American Depositary Shares (« ADS ») représentant ses actions ordinaires, est désormais effectif. Chaque ADS rep...
- Bruno Cavalier
- Ghada Ben Sedrine
- Marc Lavaud
- Nicolas David
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UNIQA INSURANCE GROUP AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ACX ACERINOX SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
01913 PRADA S.P.A.
ROS ROSENBAUER INTERNATIONAL AG
ERG ERG S.P.A.
MONC MONCLER SPA
LTA ALTAMIR ACT PORTEUR
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JUN3 JUNGHEINRICH AG PREF
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
DUE DURR AG
SFG SPHERA FRANCHISE GROUP SA
INS INSTONE REAL ESTATE GROUP AG
VK VALLOUREC SA
NA9 NAGARRO
SPAC 468 SPAC I SE
ZGN ERMENEGILDO ZEGNA NV
PLX PLUXEE NV
- Bruno Cavalier
- Ghada Ben Sedrine
- Marc Lavaud
- Nicolas David
- Thomas Zlowodzki
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
UNIQA INSURANCE GROUP AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
ACX ACERINOX SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
01913 PRADA S.P.A.
ROS ROSENBAUER INTERNATIONAL AG
ERG ERG S.P.A.
MONC MONCLER SPA
LTA ALTAMIR ACT PORTEUR
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
JUN3 JUNGHEINRICH AG PREF
SNG SOCIETATEA NATIONALA DE GAZE NATURALE ROMGAZ SA
DUE DURR AG
SFG SPHERA FRANCHISE GROUP SA
INS INSTONE REAL ESTATE GROUP AG
VK VALLOUREC SA
NA9 NAGARRO
SPAC 468 SPAC I SE
ZGN ERMENEGILDO ZEGNA NV
PLX PLUXEE NV
- Louis Boujard
- CFA
- Philippe Ourpatian
- Louis Boujard
- CFA
- Philippe Ourpatian
- Carole Braudeau
Credit Morning 11/12/2025
Carrefour has reportedly received three offers for its Romanian business, including one from Auchan.|Permira is reportedly negotiating the sale of Golden Goose for more than € 2.5bn to Hongshan|Edenred has significantly revised downwards its EBITDA forecast for 2026 if regulatory changes in Brazil are confirmed.|
- Carole Braudeau
Morning Crédit 12/11/2025
Carrefour aurait reçu trois offres pour son activité en Roumanie dont une d’Auchan.|Permira négocierait la cession de Golden Goose au fond Hongshang Capital pour plus de 2,5 mds EUR|Edenred revoit en forte baisse sa prévision d’EBITDA pour 2026 si les changements règlementaires au Brésil venaient à être confirmés.|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.